NETRF awards Dr. Jennifer Chan a Pilot Award to analyze tumor samples from a Phase II clinical trial of cabozantinib to identify biomarkers predicting response to the drug. The findings were applied in a subsequent Phase III trial, leading to approval of cabozantinib as a NET treatment in 2025.